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Tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) is known for specifically killing
cancer cells, whereas in resistant cancers, TRAIL/
TRAIL-R can promote metastasis via Rac1 and PI3K.
It remains unknown, however, whether and to what
extent TRAIL/TRAIL-R signaling in cancer cells can
affect the immune microenvironment. Here we show
that TRAIL-triggered cytokine secretion from TRAIL-
resistant cancer cells is FADD dependent and identify
the TRAIL-induced secretome to drive monocyte
polarization to myeloid-derived suppressor cells
(MDSCs) and M2-like macrophages. TRAIL-R sup-
pression in tumor cells impaired CCL2 production
and diminished both lungMDSC presence and tumor
growth. Inaccordance, the receptorofCCL2,CCR2, is
required to facilitate increased MDSC presence and
tumor growth. Finally, TRAIL and CCL2 are co-regu-
latedwithMDSC/M2markers in lungadenocarcinoma
patients. Collectively, endogenous TRAIL/TRAIL-R-
mediated CCL2 secretion promotes accumulation of
tumor-supportive immune cells in the cancer micro-
environment, thereby revealing a tumor-supportive
immune-modulatory role of the TRAIL/TRAIL-R sys-
tem in cancer biology.
INTRODUCTION
Chemo- and cytokines are central modulators of the cancer
microenvironment, which has been established as one of the hall-
mark drivers of cancer (Hanahan and Weinberg, 2011). Cancer
cells frequently modulate the cytokine milieu to alter the cellular
composition of the microenvironment in favor of tumor progres-
sion (Hanahan and Weinberg, 2011; Hoesel and Schmid, 2013;730 Molecular Cell 65, 730–742, February 16, 2017 ª 2017 The Autho
This is an open access article under the CC BY license (http://creativeQian et al., 2011). Elevated cytokine levels of interleukin-8 (IL-8),
CXCL1, CCL2, and CXCL5 have been associated with increased
growth and progression of breast, prostate, and ovarian cancer
(Begley et al., 2008; Dong et al., 2013; Fader et al., 2010; Qian
et al., 2011; Singh and Lokeshwar, 2009; Zhang et al., 2010).
These cytokines can mediate tumor-supportive effects by para-
crine recruitment and polarization of cancer-promoting myeloid
cell subsets (Chun et al., 2015; Fujita et al., 2011; Highfill et al.,
2014). Recently, two alternatively activated myeloid (M2) cell
types, CD11b+GR1+ myeloid-derived suppressor cells (MDSCs)
and fully differentiatedM2macrophages, have receivedparticular
attention. M2-like cells elicit their tumor-supportive effects by
directly promoting tumor growth as well as via immuno-suppres-
sion of antitumor effector T cells (Gabrilovich and Nagaraj, 2009;
Lesokhin et al., 2012; Mantovani and Sica, 2010; Toh et al.,
2011). It is thereforecrucial todeterminewhichsignalsare respon-
sible for creating the cytokinemilieu that enables polarization and
recruitment of an M2-like immune microenvironment.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) is amemberof theTNFsuperfamily (TNF-SF) of cytokines.
TRAIL is capable of specifically inducing apoptosis in cancer cells
via its death domain (DD)-containing receptors TRAIL-R1 and
TRAIL-R2 (also known as DR4 and DR5) (Ashkenazi et al., 1999;
Walczak et al., 1999). Although TRAIL’s apoptosis-inducing ca-
pacity has been investigated in depth, TRAIL signaling can also
induce non-apoptotic, tumor-supporting effects in apoptosis-
resistant cancer cells (Johnstone et al., 2008; Lemke et al.,
2014b; Newsom-Davis et al., 2009). We recently showed that
TRAIL signaling via TRAIL-R2 promotes invasion and metastasis
of KRAS-mutated cancers by activating Rac1/phosphatidylinosi-
tol 3-kinase (PI3K) signaling (von Karstedt et al., 2015). Impor-
tantly, this effect was cancer cell autonomous and mediated by
the membrane-proximal domain (MPD) of TRAIL-R2, indepen-
dently of the DD and the apoptosis adaptor protein Fas-associ-
ated death domain (FADD). Interestingly, the two DD-containing
TRAIL-Rs have previously been linked to the formation of a
FADD-containing secondary signaling complex associated with
nuclear factor kB (NF-kB) pathway activation, which is known tors. Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
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A Figure 1. TRAIL Induces a Cytokine Secre-
tome
(A) Schematic of the quantitative, label-free se-
cretome profiling approach.
(B and C) (B) A pool of all secreted proteins that
were upregulated by isoleucine zipper (iz)-TRAIL
(100 ng/mL) (>2-fold induction as cutoff) was
analyzed by label-free quantification and searched
for (C) the most significantly enriched GO molec-
ular functions. Line thickness is representative of
the associated p value. Chemokine activity, p =
0.0005; chemokine receptor binding, p = 0.0006;
cytokine activity, p = 0.0039.
(D) A549 cells were stimulated with iz-TRAIL
(100 ng/mL). After 24 hr, cytokine concentrations
in the cell supernatants were measured via ELISA;
cell viability was determined by CellTiter-Glo.
p values were obtained by two-tailed Student’s
t test. *p % 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001. Data are presented as mean ± SEM, n = 3.
See also Figure S1.induce cytokine secretion (Varfolomeev et al., 2005). However,
although independent studies have associated the secretion of
cytokineswith thepotential tomodulate tumor-associated inflam-
mation, neither TRAIL/TRAIL-R nor FADD-mediated signaling in
tumor cells has previously been linked with immuno-regulatory
roles in cancer (Balkwill and Mantovani, 2012; Mantovani et al.,
2008). We therefore set out to investigate whether the TRAIL/
TRAIL-R system influences the tumor immunemicroenvironment
through paracrine cytokine signaling and, if so, to what extent
endogenous TRAIL/TRAIL-R-induced modulation of the cancer
microenvironment might affect tumor growth.
RESULTS
Identification of Cytokines as Functional Drivers within
the TRAIL-Induced Secretome
Tumor-secreted factors potently influence cancer biology, and
TRAILhasshown thepotential toenhanceordisable tumorgrowth
depending on the oncogenic context. It is, however, uncharacter-Moleculaizedwhat the TRAIL-induced secretome is
constituted of in its entirety. It therefore
also remains unexplored what its biolog-
ical function in cancer might be and,
importantly,whether itmaycontain factors
of particular relevance to the described
pro-tumorigenic properties of TRAIL. We
thus conducted an unbiased proteomic
analysis of the TRAIL-induced cancer se-
cretome by mass spectrometry to identify
factors that are both secreted upon TRAIL
stimulation and functionally enriched ac-
cording to gene ontology (GO) functional
enrichment analysis (Huang et al., 2009).
Utilizing a label-free quantitative work-
flow (Figure 1A), we detected a total of
1,723proteins (TableS1, available online).
These were then quantified and used forstatistical testing of the differential abundance between TRAIL-
stimulated and unstimulated samples. Of the 1,723 detected
proteins, 720 were classified as belonging to ‘‘the secretome’’
because they were defined as secreted or membrane proteins
according to the UniProt database and/or predicted by the Pho-
bius transmembrane topology and signal peptide predictor (K€all
et al., 2004). A pool of 35 of these proteins, which were upregu-
lated greater than 2-fold by TRAIL (Figure 1B; Table S1), were
subsequently analyzed for themost significantly enrichedmolec-
ular functions, as definedbyGO terms, using the functional anno-
tation tool Database for Annotation, Visualization, and Integrated
Discovery (DAVID). This analysis revealed functional enrichment
of CXCL1, CXCL5, CCL2, IL-8, and NAMPT (Figure 1C). More-
over, CXCL1, CXCL5, CCL2, and IL-8 were highly induced, as
determinedby label-free quantification, and theonly constituents
identified in the secretome that continuously clustered together in
three separate GO molecular functions, indicating a high poten-
tial for functional significance (Figures 1B and 1C). In line with
their high potential for functional impact, CXCL1, CXCL5,r Cell 65, 730–742, February 16, 2017 731
CCL2, and IL-8 were also significantly induced by TRAIL in
different cancer cell lines, as determined by ELISA, antibody-
based cytokine array, and qPCR (Figures 1D and S1A–S1C).
We recently showed that tumor cell-expressed TRAIL and
TRAIL-R2 promote cancer progression, invasion, and metas-
tasis by cancer cell-autonomous activation of Rac1 via the
MPD of TRAIL-R2 independently of FADD (von Karstedt et al.,
2015).We therefore next testedwhether this previously identified
cell-autonomous migration pathway involved cytokine produc-
tion from cancer cells. This was, however, not the case because
conditioned supernatants of wild-type (WT) A549 cells were
incapable of rescuing the impaired migration of TRAIL-R2
knockdown (KD) cells (Figure S1D). Conversely, cytokine induc-
tion by TRAIL was also independent of Rac1 signaling because
Rac1 inhibition did not block TRAIL-mediated cytokine induction
(Figure S1E). Last, re-expression of a C-terminally truncated
TRAIL-R2 containing only the migration-inducing MPD was not
capable of inducing cytokine secretion, whereas already low
levels of re-expressed full-length TRAIL-R2 containing the DD
were sufficient to re-instate TRAIL-induced chemokine produc-
tion (Figure S1F). Together, these results demonstrate that
TRAIL must induce its secretome via a distinct mechanism.
Surviving Cancer Cells Are the Source of TRAIL-Induced
Cytokines
CD95L-induced apoptosis has recently been associated with
cytokine release from dying cells as a means of generating
‘‘find me signals’’ that assure rapid removal of dead cells (Cullen
et al., 2013).
We therefore determined whether cytokines were actively
secreted by surviving cells or passively released from dying cells
upon TRAIL treatment. To do so, we utilized TRAIL-sensitive
HeLa and HCT116 WT cells compared with TRAIL-resistant
isogenic HCT116 BAX/BAK knockout (KO) and A549 cells (Fig-
ures 2A and S2A). Killing doses of TRAIL induced very low levels
of IL-8 and CXCL1 in HCT116 WT cells (Figure 2B), whereas
stimulation of TRAIL-resistant HCT116 BAX/BAK KO cells
led to very robust secretion of IL-8 and CXCL1. In addition,
blocking cell death with the pan-caspase inhibitor Q-VD-OPh
(QVD) rescued cytokine induction in HCT116 WT and HeLa cells
(Figures 2C and S2A). Importantly, caspase activity did not affect
cytokine induction independently of its effect on cell death (Fig-
ures S2A and S2B). Supporting a central role for live cells in the
production of cytokines, sensitizing A549 cells to cell death using
the small-molecule inhibitor PIK-75, which enhances TRAIL-
induced apoptosis via the inhibition of CDK9 and consequent
downregulation of cFLIP and Mcl-1 (Lemke et al., 2014a), dras-
tically decreased TRAIL-mediated IL-8 induction as fewer live
cells were present to produce IL-8. Cell viability and cytokine
production could again be rescued by co-treatment with QVD
(Figure 2D). Collectively, these results show that cells surviving
TRAIL stimulation are the main source of TRAIL-induced cyto-
kine secretion, which is independent of caspase activity.
Caspase-8 and FADD Are Required for TRAIL-Induced
Cytokine Secretion
We next addressed the signaling requirements for TRAIL-
induced cytokine production. Because caspase activity was732 Molecular Cell 65, 730–742, February 16, 2017not required, we first sought to exclude an activity-independent
role for caspase-8. Surprisingly, KD of caspase-8 reduced
TRAIL-mediated secretion of IL-8, CXCL1, and CCL2 (Figures
3A, S3A, and S3B). Thus, TRAIL-mediated cytokine induction
requires the presence of caspase-8, but not its activity
(Figure S2B).
Because recruitment of caspase-8 to the death-inducing
signaling complex (DISC) depends on the adaptor molecule
FADD, we next assessed the effect of FADD absence on cyto-
kine production. In line with a requirement for caspase-8,
FADD deficiency entirely abrogated TRAIL-induced cytokine
secretion in human and murine lung cancer cells (Figures 3B,
S3C, and S3D). TRAIL-R surface expression levels were
comparable between WT, control (CTRL), and FADD-deficient
cells (Figure S3E). FADD deficiency did not sensitize these cells
to necroptosis because neither A549 nor murine Lewis lung
carcinoma (3LL) cells express detectable levels of RIPK3
(Figure S3F). In accord, neither cell line could be sensitized to
necroptosis by addition of second mitochondria-derived acti-
vator of caspases (SMAC) mimetics and zVAD (Figure S3G).
Importantly, the secretion of all discovered cytokines was
reinstated by reconstitution of FADD expression (Figures 3B
and S3H).
Downstream of FADD and the DISC, a secondary complex
has been associated with TRAIL-mediated gene-activatory
signaling (Varfolomeev et al., 2005). Here the role of TRADD,
a crucial adaptor in TNFR1 signaling, has remained contro-
versial, whereas its role in TNF-induced gene activation is
well established (Pobezinskaya and Liu, 2012; Hsu et al.,
1995). To explore whether TRADD might serve as an adaptor
in the secondary complex, we silenced TRADD and deter-
mined how this affected TRAIL-mediated cytokine secretion
(Figures 3A, S3A, and S3B). Interestingly, cytokine production
was significantly decreased in TRADD-silenced A549 and 3LL
cells, identifying TRADD as required for this TRAIL signaling
output.
We therefore next tested how the ablation of expression of
several other factors that are also involved in TNFR1 signaling
(Mahoney et al., 2008) affected TRAIL-induced cytokine
expression. In support of a promoting role of cIAP1/2 in
TRAIL-mediated cytokine secretion, both RNAi-mediated
silencing of cIAP1/2 as well as their pharmacological inhibition
with the SMAC mimetic compound SM-83 (Lecis et al., 2013)
decreased the levels of TRAIL-induced IL-8, CXCL1, and
CCL2 (Figures 3A, S3I, and S3J). In addition, silencing of
RIPK1 also suppressed TRAIL-induced cytokine secretion
(Figure S3B). KD of TAK1, a kinase crucial for IkB kinase
(IKK) activation and gene activation in TNFR1 signaling (Wang
et al., 2001), decreased TRAIL-induced cytokine secretion.
This effect was attributable to TAK1 kinase activity because
specific TAK1 kinase inhibition exerted similar effects (Figures
3A, S3A, S4A, and S4B).
Because absence of TRADD, cIAP1/2, or TAK1, all known in-
ducers of TNFR1 gene-activatory signaling, phenocopied FADD
deficiency regarding TRAIL’s cytokine induction, we next tested
whether FADD deficiency would affect TRAIL-induced gene-ac-
tivatory signaling. Indeed, FADD deficiency abolished IkB phos-
phorylation upon TRAIL treatment, which could be reinstated by
IL-8 CXCL1
IL-8
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Figure 2. Surviving Cancer Cells Produce
Cytokines upon TRAIL Stimulation
(A) A549, HCT116 WT, and HCT116 BAX/BAK KO
cells were stimulated with the indicated concen-
trations of iz-TRAIL for 24 hr; cell viability was
determined by CellTiter-Glo.
(B) HCT116 WT or HCT116-BAX/BAK KO cells
were stimulated with iz-TRAIL (100 ng/mL) for
24 hr; cell viability was determined by CellTiter-Glo
and cytokine concentrations in the cell superna-
tants were measured by ELISA.
(C) HCT116WT cells were pre-incubatedwith QVD
(10 mM) or DMSO for 30 min, followed by addition
of iz-TRAIL (100 ng/mL for 24 hr; cell viability and
cytokine concentrations were determined as
above.
(D) A549 cells were pre-incubated with PIK-75
(100 nM) or QVD (10 mM) + PIK-75 (100 nM)
for 30 min, followed by addition of iz-TRAIL
(100 ng/mL); cell viability and IL-8 concentration
were determined as above.
Data are presented asmean ± SEM, n = 3. See also
Figure S2.FADD reconstitution (Figure 3C), demonstrating a requirement of
FADD for TRAIL-induced gene activation. Accordingly, small-
molecule inhibition of IkB phosphorylation also abrogated cyto-
kine secretion (Figures S4C and S4D). Of note, CD95L also
induced FADD- and caspase-8-dependent cytokine secretion
in A549 cells but failed to do so in murine 3LL cells (Figures
S4E and S4F) even though the CD95L we used was able to kill
mouse embryonic fibroblasts (MEFs) (Figure S4G). The lack of
CD95L-mediated cytokine induction in 3LL cells was most likely
due to absent CD95 surface expression (Figure S4H). By
contrast, TNF-mediated cytokine induction required neither
FADD nor caspase-8 (Figures S4E and S4F). Thus, caspase-8
and FADD are required for cytokine secretion by the FADD-re-
cruiting TRAIL/TRAIL-R and CD95L/CD95 systems, but, inter-
estingly, not for cytokine induction by TNFR1.MoleculaFADD Promotes Tumor Growth and
Accumulation of Alternatively
Activated Myeloid Cells
Although evidence from non-small-cell
lung cancer (NSCLC) patients indicates
that high FADD mRNA expression corre-
lates with a poor survival prognosis
(Chen et al., 2005), mechanistic insight
into this correlation is lacking. Based on
these reports and our observed require-
ment of FADD for TRAIL-mediated cyto-
kine induction, we next investigated
whether cancer cell-expressed FADD
would affect tumor growth in vivo.
Strikingly, deletion of human FADD in
an orthotopic mouse model of NSCLC
strongly diminished lung tumor burden
(Figures 4A, 4B, S5A, and S5B). Impor-
tantly, this effect was recapitulated in a
syngeneic model wherein deletion ofmurine FADD in two independent 3LL clones significantly
impaired tumor growth, demonstrating a tumor-promoting
role of FADD across species (Figures 4C, 4D, and S5C). Of
note, FADD deficiency did not affect proliferation in vitro
(Figure S5D).
The fact that the presence of FADD in tumor cells enhances
cancer cell growth in vivo, but not in vitro, suggested that
FADD might favor tumor growth by enabling an interaction
with the tumor microenvironment. We therefore quantified the
concentration of human cytokines in murine lungs and found
that levels of IL-8, CXCL1, and CCL2, which our in vitro analysis
had identified as being induced by TRAIL in an FADD-depen-
dent manner (Figure 3B), were decreased in lungs containing
FADD-deficient tumors (Figure 4E). Since these cytokines
were previously reported to be associated with the influx ofr Cell 65, 730–742, February 16, 2017 733
Figure 3. Caspase-8 and FADD Presence
Is Required for TRAIL-Mediated Cytokine
Induction
(A) A549WT cells were transiently transfected with
small interfering RNA (siRNA) against the indicated
targets for 48 hr and stimulated with QVD (10 mM)
(CTRL) or QVD (10 mM) + iz-TRAIL (100 ng/mL);
24 hr later, cytokine concentrations were deter-
mined by ELISA. A representative western blot is
shown.
(B) A549 WT or FADD KO, either empty vector
(+EV) or FADD (+FADD) reconstituted, were stim-
ulated with iz-TRAIL (100 ng/mL) for 24 hr, fol-
lowed by determination of cytokine concentra-
tions by ELISA.
(C) Cells as in (B) were stimulated with iz-TRAIL
(100 ng/mL) for the indicated times, followed by
immunoblotting for the indicated proteins. Data
are presented as mean ± SEM, n R 3. A repre-
sentative experiment of n = 2 is shown.
See also Figures S3 and S4.GR1+ cells (Highfill et al., 2014; Toh et al., 2011), we compared
myeloid immune cell infiltration in the microenvironment
of FADD-proficient and FADD-deficient tumors. Importantly,
FADD-deficient tumors contained significantly fewer infiltrating
CD11b+GR1+ cells with lower CD206+ expression (Figures 4F,
4G, S5E, and S6H), whereas the overall levels of total CD45+
cells were comparable between the two groups (Figure S5F).
Expression of CD11b, GR1, and CD206 has been associated
with alternatively activated M2-like myeloid cells that can elicit
tumor-supportive functions (Gabrilovich and Nagaraj, 2009; Le-
sokhin et al., 2012). Therefore, FADD presence promotes the
growth of lung tumors, encourages the formation of a tumor-
supportive cytokine milieu, and increases the accumulation of
M2-like myeloid cells.
The TRAIL-Induced Secretome Polarizes Monocytes to
M2-like Cells
So far, our results established FADD presence in tumor cells
as a significant driver of both in vivo cytokine production and
the presence of alternatively activated myeloid cells. Because
we found TRAIL to induce the very same cytokines in a
FADD-dependent manner, we next investigated whether the
TRAIL-induced FADD-dependent secretome might influence
immune cell polarization. To this end, human healthy donor
CD14+ cells were cultured with supernatants of CTRL or
TRAIL-treated A549 WT or FADD KO cells (Figure 5A). Strikingly,
supernatants of WT A549 cells treated with TRAIL polarized
healthy donor CD14+ cells toward an HLA-DRlo/neg phenotype,
an immune cell population equivalent to murine CD11b+GR1+
cells (Sevko and Umansky, 2013) that we observed in vivo734 Molecular Cell 65, 730–742, February 16, 2017(Figures 4F and 5B). Furthermore, HLA-
DRlo/neg as well as HLA-DR+ cells
displayed increased levels of CD206
expression, indicating polarization to-
ward MDSC and fully differentiated M2
macrophage phenotypes, respectively
(Figures 5C and 5D). Therefore, TRAILcan trigger the secretion of myeloid cell-polarizing factors from
tumor cells in a FADD-dependent manner.
Cancer Cell-Expressed TRAIL-R Supports Tumor
Growth andRecruitment of Tumor-Supportive Infiltrates
in a Host CCR2-Dependent Manner
As the full extent of the effect of cancer cell-expressed
TRAIL-R on immune cell infiltration can most suitably be as-
sessed in immune-proficient mice, we next made use of the es-
tablished orthotopic 3LL model. Importantly, all crucial factors
identified in the TRAIL-induced secretome were also induced
by murine TRAIL in 3LL cells, with CCL2 being produced at
the highest level (Figure S6A). CCL2 was recently identified
as a crucial chemoattractant cytokine for alternatively activated
myeloid cells via its receptor, CCR2 (Chun et al., 2015). In line
with this, CCL2 expression has also been shown to polarize hu-
man peripheral blood CD11b+ cells toward an anti-inflamma-
tory CD206+ M2-phenotype (Roca et al., 2009; Sierra-Filardi
et al., 2014). Because our proteomic analysis identified
CCL2 to be among the TRAIL-induced factors with a high
potential for biological functionality, we hypothesized that stim-
ulation of cancer cell-expressed TRAIL-R may result in CCL2
production by tumor cells and, thereby, facilitate the accumula-
tion of alternatively activated M2-type cells in the tumor
microenvironment.
To test this hypothesis, we prepared stable TRAIL-R KD
(shTRAIL-R) or CTRL (pLKO.1) 3LL cells co-expressing GFP at
similar levels (Figure S6B). These cells were subsequently in-
jected into WT or CCR2-deficient mice (Figure S6B). Determina-
tion of GFP positivity in tumor-bearing lungs and histological
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Figure 5. A TRAIL-Induced Secretome Polarizes Human Monocytes to Alternatively Activated Myeloid Cells
(A) Schematic of the monocyte polarization protocol.
(B–D) CD14+ cells were isolated from healthy donor peripheral blood mononuclear cells (PBMCs) via magnetic CD14+ microbeads and incubated with untreated
or iz-TRAIL-treated (100 ng/mL) WT or FADD KO A549 conditioned medium (CM). After 48 hr, treated myeloid cells were stained with fluorochrome-labeled
antibodies against HLA-DR, CD14, and CD206 and analyzed by flow cytometry. Data are presented as fold change in HLA-DRlo/neg CD14+ cells (B), HLA-DRlo/neg,
CD14+, CD206+ cells (C), or HLA-DR+, CD14+ CD206+ macrophages (D) upon iz-TRAIL-induced CM incubation.
Unpaired, two-tailed Student’s t test was performed to determine significance. ns = p > 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± SEM, n = 4.quantification revealed a substantially lower tumor burden in WT
mice injected with shTRAIL-R 3LL (Figures 6A and 6B). This was
confirmed using different TRAIL-R-specific small hairpin RNAsFigure 4. FADD Promotes Tumor Growth and Accumulation of Alterna
(A) Severe combined immunodeficiency (SCID)/beige mice were injected with 23
vein. Tumor burden was assessed after 24 days via bioluminescence imaging. n
(B) Histological quantification of tumor burden. Representative images of H&E-s
(C) C57BL/6 mice were injected with 5 3 105 3LL cells into the lateral tail vein. L
(D) Histological quantification of tumor burden in lungs from mice shown in (
are shown.
(E) The indicated cytokines were quantified in lung homogenates by ELISA.
(F and G) Absolute number of (F) CD11b+Gr1+ or (G) CD11b+Gr1+CD206+ cells w
Unpaired, two-tailed Student’s t test was performed to determine significance. *p
Figure S5.
736 Molecular Cell 65, 730–742, February 16, 2017(shRNAs), excluding off-target effects as causative for the
observed result (Figure S6C). In vitro cell growth was similar in
pLKO.1 and shTRAIL-R cells (Figure S6D). Importantly, thetively Activated Myeloid Cells
106 A549 WT or FADD KO cells stably expressing luciferase into the lateral tail
= 11/group. Representative images are shown.
tained lung sections (53 magnification) are shown.
ung weights were determined 28 days later. Representative lungs are shown.
C). Representative images of H&E-stained lung sections (53 magnification)
ithin tumor-bearing lungs.
% 0.05, **p < 0.01, ***p < 0.001. Data are represented asmean ± SEM. See also
A B
C D E
Figure 6. Cancer Cell-Expressed TRAIL-R Supports Tumor Growth and Recruitment of Tumor-Supportive Infiltrates in a Host CCR2-Depen-
dent Manner
(A) WT or CCR2 KOmice were injected with 53 105 3LL-GFP empty vector (pLKO.1) or sh-containing vector for TRAIL-R (shTRAIL-R) cells via the lateral tail vein
and left to develop tumors for 28 days. Upon dissociation of lungs, the absolute number of tumor cells was determined by measuring GFP via fluorescence-
activated cell sorting (FACS). WT mice pLKO.1, n = 15; shTRAIL-R, n = 17; CCR2 KO mice pLKO, n = 13; shTRAIL-R, n = 11.
(B) Top: H&E staining of fixed lungs (53 magnification). Bottom: GFP-positive 3LL-containing lungs as determined by bright-field microscopy (1.53
magnification).
(C) CCL2 protein levels in lung homogenates from WT mice measured by ELISA.
(D and E) Dissociated lungs were stained with fluorochrome-labeled antibodies for (D) CD11b+GR-1+ or (E) CD11b+GR-1+CD206+ cells and analyzed by FACS.
Data are represented asmean ± SEM. Unpaired, two-tailed Student’s t test was performed to determine significance. ns = p > 0.05, *p% 0.05. See also Figure S6.difference in tumor burden between pLKO.1 and shTRAIL-R
tumors was completely absent when the host was devoid of
CCR2 (Figure 6A). Moreover, the decreased tumor burden in
mice injected with shTRAIL-R cells significantly correlated with
decreased CCL2 protein and transcript levels in shTRAIL-R
cell-containing lungs (Figures 6C and S6E). Interestingly, the
indicated difference in CCL2 protein levels was also apparent
in CCR2 KOmice, showing that it is not the mere extent of tumor
burden that determines CCL2 amounts but, instead, the ability of
tumor cells to produce CCL2, a capacity that is impaired in the
absence of TRAIL-R (Figure 6C). These results provide in vivo
evidence that expression of TRAIL-R by tumor cells is requiredfor their production of CCL2, which, in turn, mediates pro-tumor-
igenic effects via CCR2 expressed on host cells.
In line with a functional involvement of alternatively activated
myeloid cells in influencing tumor burden, the infiltration of
pLKO.1 versus shTRAIL-R 3LL tumors was significantly
decreased by shTRAIL-R in WT, but not in CCR2-deficient,
mice (Figures 6D and 6E). Thus, in the absence of host CCR2, tu-
mor cell-derived CCL2 that is induced downstream of cancer
cell-expressed TRAIL-R (Figure 6C) fails to promote thepresence
of alternatively activatedmyeloid cells in the tumormicroenviron-
ment, coincident with diminished tumor growth. In line with our
results implicating FADD as crucial for TRAIL-R-mediatedMolecular Cell 65, 730–742, February 16, 2017 737
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Figure 7. TRAIL and CCL2 Correlate with a Tumor-Supportive Immune Profile in Lung Adenocarcinoma Patients
(A–D) RNA-seq expression data from human lung adenocarcinoma biopsy samples (n = 489) were analyzed for association of TRAIL (TNFSF10)/CCL2/CCR2
expression for a curated list of immune-related genes.
(A) Heatmap of genes significantly co-expressed (p = 0.01) with TRAIL, showing log2 expression Z scores for 20% of samples with highest or lowest TRAIL
expression.
(B) Correlation data for TRAIL versus CCL2, CD33, or IL-6 expression. The statistical significance of correlations was determined using Pearson’s correlation
coefficient. The linear regression curve is shown as a red or black line for significant or non-significant correlations, respectively.
(C) As in (A) for 50% of samples with highest or lowest composite TRAIL and CCL2 expression.
(D) As in (C) for samples with highest or lowest composite TRAIL and CCR2 expression.
See also Figure S7.CCL2 secretion, 3LL FADD KO cells replicated our results
observed in CCR2 KOmice regarding tumor burden andmyeloid
infiltrates (Figures S6G and S6H). Because 3LL cells failed to
secrete cytokines in response to CD95L in vitro (Figures S4F–
S4H), we conclude that endogenous TRAIL/TRAIL-R induces
secretion ofCCL2 from tumor cells in a FADD-dependentmanner
and that this CCL2 is required to facilitate the accumulation of
tumor-promoting myeloid cells in vivo.
TRAIL and CCL2 Correlate with a Tumor-Supportive
Immune Profile in Lung Adenocarcinoma Patients
To evaluate whether TRAIL’s pro-cancer immunomodulatory
role would be reflected in cancer patient-derived gene expres-
sion data, we subjected RNA sequencing (RNA-seq) data from
a cohort of 489 lung adenocarcinoma (LUAD) patients (Cancer
Genome Atlas Research Network, 2014), obtained from the Can-
cer Genome Atlas (TCGA) (https://cancergenome.nih.gov/), to738 Molecular Cell 65, 730–742, February 16, 2017bioinformatic coexpression analysis focusing on immune cell
markers and cytokines (Table S2). Strikingly, TRAIL expression
showed a significant positive correlation with the expression of
16 M2 myeloid cell markers and cytokines associated with
their expansion (Figures 7A and 7B). Importantly, this included
CCL2 as well as CD206 (MRC1), whose murine equivalents we
found to be upregulated in mice dependent on the endogenous
TRAIL/TRAIL-R system. In line with this, expression of IL-6,
whichwe found not to be regulated by TRAIL in lung cancer cells,
also did not correlate with TRAIL expression in patients (Fig-
ure 7B). However, interestingly, many factors correlating with
TRAIL also correlated with IL-6 (Figure S7A). Since not all
patients expressing high TRAIL levels expressed low IL-6 levels
or vice versa (Figure S7B), the possibility that these two cyto-
kines might replace each other in inducing M2-like infiltrates
can be excluded. Therefore, these data support that TRAIL
does not directly induce IL-6 but suggest that both cytokines
might form part of a co-regulated cytokine network in lung
adenocarcinoma.
Our data obtained in mice, together with these human data,
suggest that a TRAIL/CCL2 axis might also be involved in modu-
lating the human tumor immunemicroenvironment. We therefore
next analyzed composite TRAIL and CCL2 high versus low
expression levels in respect to co-expression with factors
involved in M2-like cell signaling. In line with a decisive role for
TRAIL-induced CCL2 in generating an alternatively activated im-
munemicroenvironment, the expression levels of 15M2markers
and cytokines significantly correlated with composite TRAIL/
CCL2 levels (Figure 7C).
Because TRAIL/TRAIL-R-induced CCL2 elicited its tumor-
supportive effect via CCR2, we also determined whether, and
if so, which, immune cell markers and cytokines were co-regu-
lated with composite TRAIL/CCR2 expression. Here, 13 factors
were identified to significantly correlate, providing a strikingly
similar expression profile as before, with ten of these overlap-
ping with factors associated with TRAIL/CCL2 expression
(Figure 7D). Again, CD206 (MRC1) formed part of this group,
indicating its association with TRAIL/CCL2 as well as with
TRAIL/CCR2 and thereby revealing a potential connection be-
tween TRAIL, CCL2, and CCR2 in promoting M2-like myeloid
cell accumulation within human tumors. Together, these data
implicate endogenous TRAIL with an increase in tumor-sup-
portive cytokines as well as M2-myeloid markers, thereby ex-
tending the relevance of our findings to lung adenocarcinoma
patients.
DISCUSSION
Treatment with TRAIL is capable of specifically killing cancer
cells without harming non-transformed cells (Ashkenazi et al.,
1999;Walczak et al., 1999). However, some cancer cells upregu-
late TRAIL-R expression, and we recently showed that this
facilitates progression of KRAS-mutated cancers via cancer
cell-autonomous Rac1 activation independently of FADD (von
Karstedt et al., 2015). Here we identify a distinct, additional tu-
mor-supportive function of TRAIL-R signaling in cancer cells
that requires FADD. Moreover, we show that endogenous TRAIL
induces the FADD-dependent secretion of cytokines, most
importantly CCL2, resulting in polarization of myeloid cells
toward M2-like cells and the accumulation of such alternatively
activated myeloid cells in the tumor microenvironment in a
CCL2/CCR2-dependent manner, thereby contributing to tumor
growth.
Expression of TRAIL-R1 and/or TRAIL-R2, together with their
adaptor protein FADD, is known to be essential for induction of
TRAIL-induced apoptosis. Paradoxically, both receptors and
FADD have recently been independently associated with pro-
moting NF-kB induction and tumor growth, whereas a mecha-
nistic background concerning the involvement of FADD, in
particular regarding its effect on the microenvironment, has
been lacking (Bowman et al., 2015; Tang et al., 2009; Trauzold
et al., 2006). Although cell-autonomous migration of KRAS-
mutated cells was specifically mediated via the MPD of TRAIL-
R2 (von Karstedt et al., 2015), we show here that the induction
of cytokines by TRAIL does not depend on theMPD but, instead,requires the DD-mediated recruitment of FADD. Because TRAIL-
R1 as well as TRAIL-R2 express a highly conserved DD, it is
conceivable that both of these receptors are involved in TRAIL-
induced cytokine production. In line with this, stable KD of either
TRAIL-R1 or TRAIL-R2 significantly reduced TRAIL’s cytokine in-
duction (data not shown). Therefore, TRAIL/TRAIL-R-mediated,
FADD-dependent cytokine induction represents a distinct can-
cer-promoting function of this ligand-receptor system. Because
FADD absence did not affect TNF-mediated cytokine secretion,
and CD95L did not induce the secretion of cytokines from 3LL
cells, it is unlikely that these death ligands are responsible for
the decreased tumor burden observed in the syngeneic FADD-
deficient 3LL model.
As we find that TRAIL does not only induce cytokines in lung
cancer cell lines but also in colorectal and pancreatic cancer
lines, it is likely that the principal mechanism of a TRAIL-gener-
ated, tumor-supportive immune environment may also apply to
other cancer types. However, we cannot exclude that, in certain
cancers, other death ligands may facilitate the accumulation of
tumor-supportive immune cells via a similar mechanism as we
have shown for TRAIL. Indeed, our in vitro findings with CD95L
suggest that this may be the case and that, in certain cancers,
TRAIL and CD95L possibly cooperate in creating a tumor-sup-
portive immune microenviroment.
Although FADD is a crucial mediator of apoptosis, it has been
implicated in facilitating tumor promotion in hepatocellular carci-
noma (HCC) and is associated with a poor clinical outcome in
head and neck cancer and NSCLC patients (Bowman et al.,
2015; Ehlken et al., 2014; Rasamny et al., 2012). In NEMO-defi-
ciency-driven HCC, FADD deletion was shown to rescue from
aberrant apoptosis, hepatitis, and carcinoma development inde-
pendently of TRAIL-R. In contrast to HCC, lung cancer is
commonly driven by NF-kB signaling, resulting in cytokine in-
duction, whereas in this model of HCC, abrogation of NF-kB
signaling through NEMO deletion results in inflammatory cell
death, which causes cancer progression (Luedde et al., 2007;
Maeda et al., 2005; Meylan et al., 2009), implying divergent can-
cer etiologies for the two models. Analysis of how these discrep-
ancies may result in opposing roles of TRAIL-R will be interesting
to investigate in the future.
Evidence from NSCLC patients indicates that high FADD
mRNA expression correlates with a poor survival prognosis
(Chen et al., 2005). In fact, FADD has recently been shown to
promote lung cancer progression in a KRAS-driven, genetically
engineered mouse model (Bowman et al., 2015). Interestingly,
cancer cell-specific FADD deletion was also associated with
decreased myeloid infiltrates. However, a causative role of
FADD regarding immune infiltrates was not investigated. It is
therefore likely that TRAIL and its function as a promoter of a tu-
mor-supportive immune microenvironment may also play a role
in this KRAS-induced genetic model. Our data further demon-
strate that endogenous TRAIL/TRAIL-R-mediated production
of cytokines by tumor cells contributes to the polarization of
the lung microenvironment toward increased tumor-supportive,
alternatively activated myeloid infiltrates. We identify endoge-
nous TRAIL-R-induced CCL2 and its activity on host-derived
CCR2-expressing cells as crucial for the formation of a tumor-
supportive myeloid compartment because TRAIL-R-dependentMolecular Cell 65, 730–742, February 16, 2017 739
differences in tumor burden were observed in WT, but not in
CCR2-deficient, mice.
Although these experiments identify host cell expression
of CCR2 and tumor cell expression of TRAIL-R and CCL2 as
required for this pro-tumorigenic crosstalk between the
TRAIL/TRAIL-R and CCL2/CCR2 systems, the source for TRAIL
can be many fold. In the case of the A549 model, the tumor
cells themselves could serve as the source because silencing
of endogenous TRAIL reduces their cytokine secretion (data
not shown). However, many normal cell types, including various
different immune cells such as monocytes, T cells, natural killer
cells, and dendritic cells, have been shown to express TRAIL
(Fanger et al., 1999; Griffith et al., 1999; Kayagaki et al.,
1999; Mariani and Krammer, 1998; Mirandola et al., 2004)
and could therefore contribute to tumor promotion by TRAIL
and possibly even provide a positive feedback loop. Interest-
ingly, and in line with a role for TRAIL-induced cytokines in
affecting the myeloid cell compartment, the supernatant of
TRAIL-treated HT1080 cells has previously been found to
attract human macrophages in vitro (Varfolomeev et al.,
2005). Here we identify that within the TRAIL secretome,
CCL2 fulfils a central function in the formation of a tumor-sup-
portive myeloid compartment that is achieved in vivo via the
engagement of CCR2 on host cells.
Although CCL2 is described as the principal endogenous
ligand in humans and mice, CCR2 also binds CCL7, CCL8,
and CCL11 (El Khoury et al., 2007; Naert and Rivest, 2013).
Importantly, however, CCL2, whose main receptor is CCR2,
was the only CCR2 ligand we found to be induced by the
TRAIL/TRAIL-R system (data not shown). This implicates CCL2
as the CCR2 ligand that is induced by endogenous TRAIL and
mediates the CCR2-dependent modulation of the immune
environment. However, this does not preclude that other CCR2
ligands may serve a similar role in other systems.
CCL2 has been shown to enhance tumor growth in various
cancers, including prostate (Li et al., 2009), breast (Soria et al.,
2008), and lung cancer (Cai et al., 2009), and to be elevated in
the lungs of NSCLC patients (Arenberg et al., 2000; Rivas-
Fuentes et al., 2015). CCL2 has also been shown to mediate
its tumor-supportive ability by acting as a potent chemoattrac-
tant for MDSCs (Fujita et al., 2011) and unpolarized monocytes
while contributing to polarization of monocytes to MDSCs
by increasing their CD206 expression (Roca et al., 2009). As
supernatants of TRAIL-treated cells were also able to polarize
human CD14+ cells toward HLA-DRlo/neg CD206+ cells in vitro,
it is conceivable that TRAIL-induced cytokines may not only re-
cruit myeloid cells to, but also promote their polarization within,
the tumor microenvironment.
Although TRAIL’s immunomodulatory effects could be attrib-
uted to a TRAIL/TRAIL-R–CCL2/CCR2 axis, it is important to
note that TRAIL’s cancer secretome includes several other cyto-
kines associated with tumor-supportive functions. Therefore,
antagonizing TRAIL may be a therapeutic strategy to consider
for simultaneously blocking a wider protumorigenic cytokine
network as opposed to therapeutic blockade of single constitu-
ents thereof.
Our study establishes tumor cell-expressed TRAIL-R as a
trigger for cancer cells to secrete CCL2, which, in turn, drives740 Molecular Cell 65, 730–742, February 16, 2017accumulation of a pro-tumorigenic immune microenvironment
via host cell-expressed CCR2. In addition to revealing a previ-
ously unknown facet of the TRAIL system in tumor biology, the
discovered link between endogenous TRAIL/TRAIL-R signaling
and a tumor-supportive immune microenvironment suggests
that inhibiting the interaction of TRAIL with its receptors
might serve as an effective therapeutic option to limit the
presence of tumor-supportive myeloid cells within the tumor
microenvironment.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Western Blot
a-FADD BD Bioscience Cat#556402; RRID: AB_396409
a-b-Actin Sigma Cat#A1978; RRID: AB_476692
a-TRAIL-R2 Cell Signaling Cat#3696
a-caspase-8 Scaffidi et al., 1997 N/A
a-TRAIL-R1 ProSci Cat#PSC-1139-C100
a-RIP-1 BD Bioscience Cat#610458; RRID: AB_397831
a-cFLIP Adipogen Cat#AG-20B-0056-C050
Flow cytometry
a -TRAIL-R1 (HS101) Adipogen Cat#AG-20B-0022-C100
a -TRAIL-R2 (HS201) Adipogen Cat#AG-20B-0023-C100
a -TRAIL-R3 (HS301) Adipogen Cat#AG-20B-0024-C100
a -TRAIL-R4 (HS402) Adipogen Cat#AG-20B-0025-C100
a -CD45-AF700 (murine) BioLegend Cat#103127
a -CD11b-PerCP (murine) BioLegend Cat#101230
a -GR-1-PE-Cy7 (murine) BioLegend Cat#108416
a -CD274-PE (murine) eBioscience Cat#12-5982-82; RRID: AB_466089
a -CD206-FITC (murine) BioLegend Cat#141703
a -CD11c-BV711 (murine) BioLegend Cat#117349
a -F4/80-BV785 (murine) BioLegend Cat#123141
a -MHCII-BV510 (murine) BioLegend Cat#107635
a -Ly6C-BV450 (murine) BD Bioscience Cat#560594; RRID: AB_1727559
a -CD14-APC (human) BD Bioscience Cat#555397
a -HLA-DR-FITC (human) BD Bioscience Cat#556643
a -HLA-DR-APC-H7 (human) BD Bioscience Cat#641393
a -CD206-PerCP-Cy5.5 (human) BioLegend Cat#321121
a -CD11b-PE (human) BD Bioscience Cat#555388
Chemicals, Peptides, and Recombinant Proteins
iz-TRAIL Ganten et al., 2006 N/A
FLAG-TRAIL Ganten et al., 2006 N/A
D-Luciferin, firefly (in vivo) GoldBIO Cat#LUCK-1G
RBC lysis buffer Cambridge Bioscience Cat#420301
fixable viability dye eFluor780 eBioscience Cat#65-0865-14
Fc block BioLegend Cat#422302
Critical Commercial Assays
Human Cytokine Array kit R&D Systems Cat#ARY005
Human CCL2/MCP-1 DuoSet ELISA R&D Systems Cat#DY279
Human CXCL1/GRO alpha DuoSet ELISA R&D Systems Cat#DY275
Human CXCL8/IL-8 DuoSet ELISA R&D Systems Cat#DY208
Human CXCL5/ENA-78 DuoSet ELISA R&D Systems Cat#DY254
Mouse CCL2/JE/MCP-1 DuoSet R&D Systems Cat#DY479
Mouse CCL5/RANTES DuoSet R&D Systems Cat#DY478
Mouse CXCL1/KC DuoSet ELISA R&D Systems Cat#DY453
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CellTiter-Glo Promega Cat#G7572
Cell proliferation assay kit Millipore Cat#2750
anti-CD14 coated microbeads Milteny Biotec Cat#130-050-201
RNeasy mini spin kit QIAGEN Cat#74104
RevertAid First Strand cDNA synthesis kit Thermo Fisher Cat#K1632
Deposited Data
The TRAIL-induced cancer secretome This paper ProteomeXchange: PXD005664
Experimental Models: Cell Lines
A549-luc Caliper Life Science Bioware Cell Line A549-Luc-C8
3LL Provided by S. Quezada N/A
Colo357 Provided by A. Trauzold N/A
HCT116 WT Provided by B. Vogelstein N/A
HCT116 Bax/Bak KO Provided by B. Vogelstein N/A
HeLa Cell stock N/A
Experimental Models: Organisms/Strains
Mice (C57BL/6) Charles River UK C57BL/6NCrl
Mice (Fox Chase SCID Beige) Charles River UK CB17.Cg-PrkdcscidLystbg-J/Crl
Recombinant DNA
MSCV-IRES-GFP Provided by V. Horejsi N/A
Sequence-Based Reagents
MISSION pLKO.1-puro Empty Vector Control Plasmid DNA Sigma Cat#SHC001
mTRAIL-R shRNA set Sigma Cat#SHCLND-NM_020275
ON-TARGETplus RIPK1 siRNA smart pool GE Dharmacon Cat#L-004445-00-0005
ON-TARGETplus Mouse Tradd (71609) siRNA - SMARTpool GE Dharmacon Cat#L-061669-00-0005
ON-TARGETplus Mouse Casp8 (12370) siRNA - SMARTpool GE Dharmacon Cat#L-043044-00-0005
ON-TARGETplus Human TRADD (8717) siRNA - SMARTpool GE Dharmacon Cat#L-004452-00-0005
ON-TARGETplus Human MAP3K7 (6885) siRNA - SMARTpool GE Dharmacon Cat#L-003790-00-0005
siGENOME Non-Targeting siRNA #1 GE Dharmacon Cat#D-001210-01-05
siGENOME Human CASP8 (841) siRNA - Set of 4 Upgrade GE Dharmacon Cat# MU-003466-05-0005
ON-TARGETplus Human BIRC3 siRNA - SMARTpool GE Dharmacon Cat# L-004099-00-0005
ON-TARGETplus Human BIRC2 (329) siRNA - SMARTpool GE Dharmacon Cat# L-004390-00-0005
Software and Algorithms
MaxQuant version 1.4.1.2 N/A N/A
MSstats converter script http://msstats.org/ N/A
Phobius http://phobius.sbc.su.se/ N/A
DAVID Bioinformatics Resources 6.7 https://david.ncifcrf.gov/ N/A
limma R package https://bioconductor.org/packages/
release/bioc/html/limma.html
N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to the Lead Contact, Prof. Henning Walczak (h.walczak@ucl.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
All animal experiments were conducted under an appropriate animal project license approved by the UK home office and held by
H. Walczak, in accordance with the revised (2013) Animals (Scientific Procedures) Act (ASPA) and the institutional guidelines of
the UCL Cancer Institute. The required risk assessments were obtained for this study. All healthy human donors gave their approval
for use of their blood for this research.e2 Molecular Cell 65, 730–742.e1–e5, February 16, 2017
METHOD DETAILS
A549-luc lung cancer xenograft
6-8 week-old female SCID beige mice were obtained from Charles River (UK) and injected with 2 3 106 A549-luc control or FADD
knockout cells into the lateral tail vein. 30min after cell injection, micewere injectedwith Luciferin (GoldBIO) and imaged for luciferase
activity using the Xenogen system to verify presence of cells in the lung. Imaging was repeated weekly for 3 weeks. Animals were
euthanized and lungs analyzed for immune infiltrates and by histology.
3LL syngeneic lung cancer model
6-8 week-old C57BL/6 mice of mixed genders were obtained from Charles River (UK) and injected with 5 3 105 3LL cells stably ex-
pressing pLKO.1 control or an shRNA against mTRAIL-R as well as a GFP reporter construct. CCR2 KO mice, on C57BL/6 back-
ground, were kindly provided by D. Gilroy. Tumors were left to develop for 4 weeks followed by immune-cell analysis and histology.
Histology
Lungs were fixed in 10% Formalin (Sigma), for 48 hr, paraffin-embedded and cut into 5 mm sections. Subsequently, paraffin sections
were H&E-stained. Tumor burden was quantified as% lung covered by tumor tissue as determined by an experienced pathologist in
a blinded manner.
Flow Cytometry
Lungs were cut into small pieces followed by passage through a 40uM Nylon filter (BD). Red blood cells were lysed for 5 min at room
temperature (RT) in RBC lysis buffer (BioLegend). Cells were then labeled with fixable viability dye eFluor780 (eBioscience) for 30 min
in the dark at RT, followed by Fc block (BD Biosciences). Antibodies used were against CD45-AF700, CD11b-PercpCy5.5, CCR2-
AlexaFluor647, GR-1-PE-Cy7, CD274-PE, CD206-FITC, CD11c-BV711, F4-80-BV785, MHCII-BV510, Ly6C-BV450 (detailed in the
Key Resources Table). Human monocyte-derived macrophages and MDSC were stained with antibodies against CD14-APC, HLA-
DR-FITC, HLA-DR-APC-H7, CD206-PE-Cy5, CD11b-PE (Key Resources Table). Intracellular staining was performed using an Intra-
cellular Fixation and Permeabilization Buffer Set (eBioscience) according to themanufacturer’s instructions. Fluorescenceminus one
(FMO) controls were used to distinguish between positively and negatively stained cells. Flow cytometric analysis was performed
with a LSRFORTESSA X-20 (BD) or Accuri (BD) with subsequent data analysis using FlowJo software.
Cell culture and lentiviral infection
HeLa, 3LL and HCT116 cells were cultured in DMEM supplemented with 10% FCS, COLO357 in RPMI1640 supplemented with 10%
FCS, 2 mM Glutamine and 1 mM sodium pyruvate and A549-luc cells in RPMI1640 supplemented with 10% FCS. All cell lines were
mycoplasma-free as determined byMycoAlertMycoplasma Detection Kit (LONZA). To generate shTRAIL-R 3LL cells, parental 3LL
cells were infected with pLKO.1 vector control or shRNA, against TRAIL-R, carrying lentiviral particles for 48 hr. Both vector and
shRNA were purchased from Sigma. After selection with 12ug/ml Puromycin, KD efficiency was verified by western blot.
RNA interference
Cells were transiently transfected with siRNA pools (ON-TARGET plus or siGENOME) containing four different siRNA sequences tar-
geting each gene of interest or Non-targeting control siRNA. All siRNA pools were purchased from Dharmacon/Thermo Scientific
(Loughborough, UK). Cells were transfected using Dharmafect reagent according to the manufacturer’s instructions. Cells were
used for further analysis at 48 or 72 hr after transfection as indicated in the figure legends. KD efficiency was confirmed by western
blotting.
Production of knockout cell lines
A549 FADD KO were generated via zinc finger nucleases (Sigma) targeting exon 1 of FADD. Cells were transfected using Lipofect-
amine 2000 according tomanufacturer instructions. Limiting dilutionwas employed to achieve single cell cloning, whichwas followed
by KO validation via western blot.
3LL FADD KO were generated via clustered regularly interspaced short palindromic repeats (CRISPR)-Cas-9 technology by tar-
geting exon 2 of murine FADD. The cells were transfected, subjected to single cell cloning and validated as above.
Retroviral transduction of cells
WT FADDwas inserted into the retroviral MSCV vector, followed by an internal ribosome entry site (IRES) and the open reading frame
of EGFP. Lipofectamine 2000 was used to transfect the vector construct into Phoenix cells. The medium was changed 24h post-
transfection followed by collection of viral supernatants after 72h. The viral supernatants were then filtered through a 0.45 mm filter
and added to the cells in presence of polybrene (6 mg/ml) followed by spinfection (2500 rpm, 45min, 30C). EGFP positive single cells
were then sorted into 96w plates using BDAria.Molecular Cell 65, 730–742.e1–e5, February 16, 2017 e3
Lysates, Western Blots and antibodies
Cells were lysed in IP-lysis buffer (30 mM Tris-HCl [pH 7.4], 120 mMNaCl, 2 mM EDTA, 2 mM KCl, 1% Triton X-100, 13 COMPLETE
protease-inhibitor cocktail) at 4C for 30 min. Proteins were separated by SDS-PAGE (NuPAGE) and analyzed by western blotting.
Membranes were stripped with 50 mM glycine (pH 2.3) before reprobing with other antibodies (detailed in the Key Resources Table).
ELISA and Cytokine arrays
The respective cells were stimulated with iz-TRAIL [100ng/ml]. After 24h, cells were spun at 1500rpm for 3min followed by removal of
supernatants. Cytokine levels in the cell supernatants were determined via ELISAs or human cytokine array, according to the man-
ufacturer’s instructions (R&D systems).
RNA isolation, cDNA synthesis, and real-time qPCR analysis
Total RNAwas extracted from cells or tissues (QIAGEN kit), treated with DNase1 (Life technologies) and reverse transcribed using the
RevertAid First Strand cDNA synthesis kit (Fermentas). qPCR synthesis reactions were performed in 96-well plates with 50ng of
cDNA on a Realplex Mastercycler (Eppendorf). Relative mRNA levels were calculated using the DDCt method normalized to GAPDH
mRNA.
Viability and Cell proliferation assays
Cell viability was determined by CellTiter-Glo assay (Promega) according to the manufacturer’s instructions. Cell proliferation was
determined by BrdU incorporation (Cell proliferation assay kit, Millipore) according to the manufacturer’s instructions.
Luciferase Assay
Stable A549-luc cells were seeded in 96-well plates at the indicated numbers. 24h later, medium was removed and the cells were
incubated with 30 ml of Permeabilization Buffer (eBioscience) for 15 min. Subsequently, the cells were incubated with 30 ml Firefly
luciferin-containing buffer (Luciferase Assay buffer) for 10 min. A Mithras plate reader was used to determine relative luminescence.
Monocyte differentiation
A549 supernatants were generated by stimulating with iz-TRAIL in RPMI1640 for 2h, followed by 2 washes with PBS and centrifu-
gation at 5000rpm for 5min. PBMCs from healthy adult donors were isolated via Ficoll density gradient centrifugation. CD14+ mono-
cyte isolation was conducted using anti-CD14 coated microbeads (Milteny Biotec), followed by purity analysis via flow cytometry.
Monocytes were cultured at 1x106 cells/ml in A549 supernatants supplemented with 10% human serum; 48h later the differentiation
state was determined via flow cytometry.
Sample preparation for mass spectrometry
Proteins were denatured with 6M urea in 50mM ammonium bicarbonate (AB). Denatured proteins were reduced with 4mM dithio-
threitol (DTT) in 50mM AB at 56C for 25min, cooled to room temperature and alkylated with 8mM iodoacetamide in 50mM AB at
room temperature in the dark for 30min. The excess of iodoacetamide was removed with an additional 4mM DTT in 50mM AB.
Urea concentration was then diluted to 1.5M with 50mM AB. Proteins were digested with sequencing grade trypsin (Promega) at
a 1:50 protease to protein ratio at 37C for 15h. Digestion was stopped with 1% trifluoroacetic acid (TFA). Peptide digests were de-
salted with microspin columns filled with SEM. SS18V silica (The Nest Group), eluted with 50% acetonitrile 0.1% TFA, evaporated to
dryness at 30C, and resolubilized in 20mL of 10% formic acid in water. 1-2mL of peptides was used for nLC-MS analysis.
Mass spectrometry
nLC-MS/MS was performed on a Q Exactive Orbitrap interfaced to a NANOSPRAY FLEX ion source and coupled to an Easy-nLC
1000 (Thermo Scientific). Peptides were separated on a 20cm fused silica emitter, 75mm diameter, packed in-house with Repro-
sil-Pur 200 C18-AQ, 2.4mm resin (Dr.Maisch) using a linear gradient from 5% to 30% acetonitrile/ 0.1% formic acid over 4h, at a
flow rate of 300 nL/min. Precursor ions were measured in a data-dependent mode in the orbitrap analyzer at a resolution of
70,000 and a target value of 1e6 ions. The ten most intense ions from each MS1 scan were isolated, fragmented in the HCD cell,
and measured in the orbitrap at a resolution of 17,500. The total protein content of the concentrated secretome was determined
with the Bicinchoninic acid (BCA) assay. An equal protein load was used across conditions, which was in the range of 10-100ug be-
tween replicate experiments.
QUANTIFICATION AND STATISTICAL ANALYSIS
In vivo bioluminescence quantification
Photon flux was determined by Xenogen software quantifying photons per second in a defined region of interest (ROI).e4 Molecular Cell 65, 730–742.e1–e5, February 16, 2017
Immune cell quantification by Flow cytometry
Flow cytometric reference beads (Invitrogen) were mixed to the samples before analysis for quantification of immune cell subsets in
each lung. The absolute number (Abs) of cells was calculated using the following formula: Abs = (count of gated cells/count of beads)/
number of beads added to the sample.
Statistics
Data were analyzed using the GraphPad Prism 6 software (GraphPad Software). Results are means ± SEM. Statistical significance
between groups was determined using Student’s t test. A p value of < 0.05 was considered statistically significant and indicated
with *, p < 0.01 = ** and p < 0.001 = ***. ns = non-significant.
Mass spectrometric data analysis
Raw data were analyzed withMaxQuant version 1.4.1.2 where they were searched against the human UniProt database (http://www.
uniprot.org/, downloaded 03/04/2013) using default settings. Carbamidomethylation of cysteines was set as fixed modification, and
oxidation of methionines and acetylation at N-termini were set as variable modifications. Enzyme specificity was set to trypsin with
maximally 2 missed cleavages allowed. To ensure high confidence identifications, PSMs, peptides, and proteins were filtered at a
less than 1% false discovery rate (FDR). The label-free quantification workflowwas used with a match time window of 4min, an align-
ment time window of 20mins, and a match between runs selected. Statistical protein analysis was performed with
MSstats.daily_2.3.4 (Choi et al., 2014). MaxQuant output was converted to the MSstats required format with a converter script
from the MSstats website (http://msstats.org/). p values were adjusted to control for the false discovery rate using the Benjamini-
Hochberg procedure (Benjamini and Hochberg, 1995). Quantified proteins were annotated with cellular compartments reported in
UniProt and predicted with the transmembrane topology and signal peptide predictor Phobius (http://phobius.sbc.su.se/). Identified
intracellular contaminants were removed, and secreted and membrane proteins were retained to comprise the secretome. Upregu-
lated secretome proteins by at least two fold upon TRAIL treatment were submitted to DAVID Bioinformatics Resources 6.7 for
enrichment analysis of gene ontology molecular function terms. The quantification of proteins associated with the top three enriched
molecular functions (chemokine activity, chemokine receptor binding, cytokine activity) were visually inspected and in cases where
noisy peptide features were present (standard error > 0.3) or where peptide features were not extracted in all replicates byMaxQuant,
the peptide with the highest signal to noise ratio for that protein was reanalyzed in Skyline (MacLean et al., 2010) by targeted data
quantification. A student’s paired t test with a one-tail distribution was used for the comparisons of means.
TCGA expression analysis
RNaseq V2 level 3 data were downloaded for 489 LUAD samples from the TCGA data portal and parsed using a custom R function.
The RSEM expression values were transformed to log2 counts per million using the voom function from the limma R package. High
and Low composite groups for TRAIL & CCL2, or TRAIL & CCR2, were defined using overlapping samples for both genes of a pair in
the top and bottom 50%of expression values. Differentially expressed genes were determined using limma-trend at a BH-adjusted p
value of 0.01 and a two-fold change in expression between the composite high and low groups and were filtered to a curated list of
immune factors for visualization on heatmaps.
DATA AND SOFTWARE AVAILABILITY
Expression data from the LUAD patient cohort were downloaded from the Cancer Genome Atlas (TCGA) Research Network and can
be obtained at https://cancergenome.nih.gov/. The accession number for the ‘‘TRAIL-induced cancer secretome’’ dataset reported
in this paper is ProteomeXchange: PXD5664 and can be obtained at http://www.ebi.ac.uk/pride.Molecular Cell 65, 730–742.e1–e5, February 16, 2017 e5
